Literature DB >> 7812969

Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation.

J A Nagy1, E M Masse, K T Herzberg, M S Meyers, K T Yeo, T K Yeo, T M Sioussat, H F Dvorak.   

Abstract

Previous studies have shown that accumulation of tumor ascites fluid results in large part from increased permeability of peritoneal lining vessels (Nagy et al., Cancer Res., 49: 5449-5458, 1989; Nagy et al., Cancer Res., 53: 2631-2643, 1993). However, the specific microvessels rendered hyperpermeable have not been identified nor has the basis of peritoneal vascular hyperpermeability been established. To address these questions, TA3/St and MOT carcinomas, well-characterized transplantable murine tumors that grow in both solid and ascites form, were studied as model systems. Ascites tumor cells of either type were injected i.p. into syngeneic A/Jax and C3Heb/FeJ mice, and ascites fluid and plasma were collected at intervals thereafter up to 8 and 28 days, respectively. Beginning several days after tumor cell injection, small blood vessels located in tissues lining the peritoneal cavity (mesentery, peritoneal wall, and diaphragm) became hyperpermeable to several macromolecular tracers (125I-human serum albumin, FITC-dextran, colloidal carbon, and Monastral Blue B). Increased microvascular permeability correlated with the appearance in ascites fluid of vascular permeability factor (VPF), a tumor cell-secreted mediator that potently enhances vascular permeability to circulating macromolecules. VPF was measured in peritoneal fluid by both a functional bioassay and a sensitive immunofluorometric assay. The VPF concentration, total peritoneal VPF, ascites fluid volume, tumor cell number, and hyperpermeability of peritoneal lining microvessels were found to increase in parallel over time. The close correlation of peritoneal fluid VPF concentration with the development of hyperpermeable peritoneal microvessels in these two well-defined ascites tumors suggests that VPF secretion by tumor cells is responsible, in whole or in part, for initiating and maintaining the ascites pattern of tumor growth.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7812969

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  80 in total

Review 1.  Role of vascular permeability factor/vascular endothelial growth factor in eye disease.

Authors:  R O Schlingemann; V W van Hinsbergh
Journal:  Br J Ophthalmol       Date:  1997-06       Impact factor: 4.638

2.  TGF-beta blockade controls ascites by preventing abnormalization of lymphatic vessels in orthotopic human ovarian carcinoma models.

Authors:  Shan Liao; Jieqiong Liu; Peichun Lin; Tony Shi; Rakesh K Jain; Lei Xu
Journal:  Clin Cancer Res       Date:  2011-01-28       Impact factor: 12.531

Review 3.  Ascorbic acid: chemistry, biology and the treatment of cancer.

Authors:  Juan Du; Joseph J Cullen; Garry R Buettner
Journal:  Biochim Biophys Acta       Date:  2012-06-20

4.  Safety, Efficacy, and Biomarker Exploration in a Phase II Study of Bevacizumab, Oxaliplatin, and Gemcitabine in Recurrent Müllerian Carcinoma.

Authors:  Neil S Horowitz; Richard T Penson; Dan G Duda; Emmanuelle di Tomaso; Yves Boucher; Marek Ancukiewicz; Kenneth S Cohen; Suzanne Berlin; Carolyn N Krasner; Marsha A Moses; Rakesh K Jain
Journal:  Clin Ovarian Cancer Other Gynecol Malig       Date:  2011-06

5.  Transcellular diapedesis is initiated by invasive podosomes.

Authors:  Christopher V Carman; Peter T Sage; Tracey E Sciuto; Miguel A de la Fuente; Raif S Geha; Hans D Ochs; Harold F Dvorak; Ann M Dvorak; Timothy A Springer
Journal:  Immunity       Date:  2007-06       Impact factor: 31.745

6.  Targeting a metalloprotease-PAR1 signaling system with cell-penetrating pepducins inhibits angiogenesis, ascites, and progression of ovarian cancer.

Authors:  Anika Agarwal; Lidija Covic; Leila M Sevigny; Nicole C Kaneider; Katherine Lazarides; Gissou Azabdaftari; Sheida Sharifi; Athan Kuliopulos
Journal:  Mol Cancer Ther       Date:  2008-09       Impact factor: 6.261

7.  Molecular framework for angiogenesis: a complex web of interactions between extravasated plasma proteins and endothelial cell proteins induced by angiogenic cytokines.

Authors:  D R Senger
Journal:  Am J Pathol       Date:  1996-07       Impact factor: 4.307

8.  Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy.

Authors:  G S Robinson; E A Pierce; S L Rook; E Foley; R Webb; L E Smith
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-14       Impact factor: 11.205

9.  Antiangiogenic gene therapy with soluble VEGFR-1, -2, and -3 reduces the growth of solid human ovarian carcinoma in mice.

Authors:  Hanna Sallinen; Maarit Anttila; Johanna Narvainen; Jonna Koponen; Kirsi Hamalainen; Ivana Kholova; Tommi Heikura; Pyry Toivanen; Veli-Matti Kosma; Seppo Heinonen; Kari Alitalo; Seppo Yla-Herttuala
Journal:  Mol Ther       Date:  2008-12-02       Impact factor: 11.454

10.  Visualization of tumor angiogenesis using MR imaging contrast agent Gd-DTPA-anti-VEGF receptor 2 antibody conjugate in a mouse tumor model.

Authors:  Hong Young Jun; Hong-Hua Yin; Sun-Hee Kim; Seong Hoon Park; Hun Soo Kim; Kwon-Ha Yoon
Journal:  Korean J Radiol       Date:  2010-06-21       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.